Design, Properties, and Effective Use of the Oral Chelator L1 and Other
1990; Wiley; Volume: 612; Issue: 1 Linguagem: Inglês
10.1111/j.1749-6632.1990.tb24321.x
ISSN1749-6632
Autores Tópico(s)Head and Neck Cancer Studies
ResumoAnnals of the New York Academy of SciencesVolume 612, Issue 1 p. 339-350 Design, Properties, and Effective Use of the Oral Chelator L1 and Other α-Ketohydroxypyridines in the Treatment of Transfusional Iron Overload in Thalassemiaa GEORGE J. KONTOGHIORGHES, GEORGE J. KONTOGHIORGHES Department of Haematology Royal Free Hospital School of Medicine London NW3 2QG United KingdomSearch for more papers by this author GEORGE J. KONTOGHIORGHES, GEORGE J. KONTOGHIORGHES Department of Haematology Royal Free Hospital School of Medicine London NW3 2QG United KingdomSearch for more papers by this author First published: December 1990 https://doi.org/10.1111/j.1749-6632.1990.tb24321.xCitations: 36 a This work was supported by the U.K. Thalassaemia Society. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Angastiniotis, M. 1989. Cost of desferrioxamine treatment. In Abstracts of the 1st International Symposium on Oral Chelators in the Treatment of Thalassaemia and Other Diseases. London, UK.: 34. Google Scholar 2 Modell, B. & V. Berdoukas. 1984. The Clinical Approach to Thalassaemia. Grune and Stratton. London . Google Scholar 3 Kontoghiorghes, G. J., M. A. Aldouri, L. Sheppard & A. V. Hoffbrand. 1987. 1,2-Dimethyl-3-hydroxypyrid-4-one: An orally active chelator for the treatment of iron overload Lancet.. i: 1294–1295. 10.1016/S0140-6736(87)90545-9 CASGoogle Scholar 4 Kontoghiorghes, G. J., M. A. Aldouri, A. V. Hoffbrand, J. Barr, B. Wonke, T. Kourouclaris & L. Sheppard. 1987. Effective chelation of iron in β-thalassaemia with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Br. Med. J.. 295: 1509–1512. 10.1136/bmj.295.6612.1509 CASPubMedWeb of Science®Google Scholar 5 Kontoghiorghes, G. J., A. N. Bartlett & A. V. Hoffbrand. 1989. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other α-ketohydroxypyridines Prog. Clin. Biol. Res.. 309: 107–114. CASPubMedGoogle Scholar 6 Kontoghiorghes, G. J. 1987. Iron chelation in biochemistry and medicine. In Free Radicals Oxidant Stress and Drug Action. C. Rice-Evans, Ed.: 277–303. Richelieu Press. London . Google Scholar 7 Kontoghiorghes, G. J. & A. V. Hoffbrand. 1988. Prospects for effective and oral chelation in transfusional iron overload Recent Adv. Haematol.. 5: 75–98. Google Scholar 8 Kontoghiorghes, G. J. 1982. The design of orally active iron chelators for the treatment of thalassaemia. Ph.D. Thesis. Essex University. British Library microfilm D 66794/86. Google Scholar 9 Kontoghiorghes, G. J. 1987. Structure/iron binding activity of 1-hydroxypyrid-2-one chelators intended for clinical use Inorg. Chim. Acta. 135: 145–150. 10.1016/S0020-1693(00)83279-X CASWeb of Science®Google Scholar 9a Lott, W. A. & E. Shaw. 1949. Analogs of Aspergillic acid: II Various antibacterial heterocyclic hydroxamic acids. J. Am. Chem. Soc.. 71: 70–73. 10.1021/ja01169a020 CASPubMedWeb of Science®Google Scholar 10 Pitt, C. G. & G. Gupta. 1975. The design and synthesis of chelating agents for the treatment of iron overload in Cooley's anaemia. In: Proceedings of the Symposium on Development of Iron Chelators for Clinical Use. W. F. Andreson & M. C. Hiller, Eds.: 137–168. NIH. Bethseda . Google Scholar 11 Grady, R. W., J. H. Graziano, G. P. White, A. Jacobs & A. Cerami. 1978. The development of new iron chelating drugs (ii) J. Pharmacol. Exp. Ther.. 205: 757–765. CASWeb of Science®Google Scholar 12 Tsai, W. C. & K. H. Ling. 1973. Study of the stability constant of some metal ion chelates of mimosine and 3,4-dihydroxypyridine J. Chin. Biochem. Soc.. 2: 70–86. CASGoogle Scholar 13 Tsai, W. C. & K. H. Ling. 1971. Effect of metals on the absorption and excretion of misosine and 3,4-dihydroxypyridine in rat in vivo. J. Formosan Med. Assoc. 73: 543–549. PubMedGoogle Scholar 14 Lin, J. Y. & K. H. Ling. 1961. Studies on free amino acids in the seeds of Leucaena Glauca Benth: III, Biological study on mimosine J. Formosan Med. Assoc.. 60: 657–664. CASPubMedGoogle Scholar 15 Rennhard, H. H. 1971. The metabolism of ethyl maltol and maltol in the dog J. Agric. Food Chem.. 19: 152–154. 10.1021/jf60173a036 CASPubMedWeb of Science®Google Scholar 16 Ziller, S. A. 1977. Absorption, excretion and tissue distribution of 2-pyridinethiol-1-oxide Food Cosmet. Toxicol.. 15: 49–54. 10.1016/S0015-6264(77)80263-0 CASPubMedWeb of Science®Google Scholar 17 Harris, R. L. N. 1976. Potential wool growth inhibitors: Improved synthesis of mimosine and related 4-(1H)-pyridones Aust. J. Chem.. 29: 1329–1334. 10.1071/CH9761329 CASWeb of Science®Google Scholar 18 Mohrle, H. & H. Weber. 1970. Zur Kenntnis Der 1-methyl-3-hydroxypyridone-(2) und-(6) Tetrahedron. 26: 3779–3783. 10.1016/S0040-4020(01)92954-0 Web of Science®Google Scholar 19 Mizukami, S., L. Hirai & M. Morimoto. 1966. A new series of pyridine-1-oxides Annu. Rep. Shionogi Res. Lab.. 16: 29–36. CASGoogle Scholar 20 Kontoghiorghes, G. J. 1986. Orally active α-ketohydroxypyridine iron chelators: Studies in mice Mol. Pharmacol.. 30: 670–673. CASPubMedWeb of Science®Google Scholar 21 Hider, R. C., G. J. Kontoghiorghes & J. Silver. 1983. Pharmaceutical Compositions. UK Patent Application 2118176. Google Scholar 22 Kontoghiorghes, G. J. & L. Sheppard. 1989. Process for Producing Pyrid-4-ones. European Patent Application no. 0335745. Google Scholar 23 Kontoghiorghes, G. J., J. Barr & L. Sheppard. 1988. Selection of novel oral iron chelators for the treatment of transfusional iron overload and other diseases of iron imbalance and toxicity Blood. 72: 64. Google Scholar 24 Kontoghiorghes, G. J. & L. Sheppard. 1987. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones Inorg. Chim. Acta. 136: L11–L12. 10.1016/S0020-1693(00)85549-8 CASWeb of Science®Google Scholar 25 Kontoghiorghes, G. J., L. Sheppard & J. Barr. 1988. Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-ones. Inorg. Chim. Acta 152: 195–199. 10.1016/S0020-1693(00)84951-8 CASWeb of Science®Google Scholar 26 Kontoghiorghes, G. J. 1985. New orally active iron chelators Lancet. i: 817. 10.1016/S0140-6736(85)91472-2 CASGoogle Scholar 27 Kontoghiorghes, G. J. 1986. Dose response studies using desferrioxamine and orally active chelators in a mouse model Scand. J. Haematol.. 37: 63–70. 10.1111/j.1600-0609.1986.tb01773.x CASPubMedWeb of Science®Google Scholar 28 Kontoghiorghes, G. J. & A. V. Hoffbrand. 1986. Orally active α-ketohydroxypyridine iron chelators intended for clinical use: In vivo studies in rabbits. Br. J. Haematol. 62: 607–613. 10.1111/j.1365-2141.1986.tb04082.x CASPubMedWeb of Science®Google Scholar 29 Kontoghiorghes, G. J. 1990. L1NAll: 1-Allyl-2-methyl-3-hydroxypyrid-4-one Drugs Future. 15: 230–232. Google Scholar 30 Huehns, E. R., J. B. Porter & R. C. Hider. 1988. Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models Haemoglobin. 12: 593–600. 10.3109/03630268808991649 CASPubMedWeb of Science®Google Scholar 31 Kontoghiorghes, G. J., P. Nasseri-Sina, J. G. Goddard, J. M. Barr, P. Nortey & L. Sheppard. 1989. Safety of oral iron chelator L1 Lancet.. ii: 457–458. 10.1016/S0140-6736(89)90642-9 Google Scholar 32 Porter, J. B., K. P. Hayes, R. Abeysinghe, E. R. Huehns & R. C. Hider. 1989. Animal toxicology of iron chelator L1 Lancet.. ii: 56. Google Scholar 33 Kontoghiorghes, G. J. & A. V. Hoffbrand. 1989. Clinical trials with oral iron chelator L1 Lancet.. ii: 1516–1517. 10.1016/S0140-6736(89)92952-8 Google Scholar 34 Zervas, J., D. Kyriakou, K. Konstantopoulos, K. Sofroniadou, M. Matzourani, C. Tsekoura, E. Demertzi & P. Fessas. 1989. Acute myelopathy after high dose desferrioxamine administration intravenously. In Abstracts of the 3rd International Conference on Thalassaemia and the Hemoglobinopathies. Cagliari, Italy.: 167. Google Scholar 35 Hoffbrand, A. V., A. N. Bartlett, P. Veys, N. T. J. O'Connor & G. J. Kontoghiorghes. 1989. Agranulocytosis and thrombocytopenia in a patient with Blackfan Diamond anaemia during oral chelator trial Lancet.. ii: 457. 10.1016/S0140-6736(89)90641-7 CASGoogle Scholar 36 Broxmeyer, H. E., P. Gentile, J. Bognacki & P. Ralph. 1983. Lactoferrin, transferrin and acidic isoferritins: Regulatory molecules with potential therapeutic value in Leukemia Blood Cells. 9: 83–105. CASPubMedWeb of Science®Google Scholar 37 Matsakis, M., P. Nasseri-Sina & G. J. Kontoghiorghes. 1989. Preliminary histopathological results of the effects of subacute doses of L1 in normal and iron loaded rats. In Abstracts of the 1st International Symposium on Oral Chelation in the Treatment of Thalassaemia and Other Diseases. London, UK.: 37. Google Scholar 37a Kontoghiorghes, G. J., J. G. Goddard, A. N. Bartlett & L. Sheppard. 1990. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxyprid-4-one. Clin. Pharmacol. Ther. In press. 10.1038/clpt.1990.147 PubMedWeb of Science®Google Scholar 38 Goddard, J. G. & G. J. Kontoghiorghes. 1990. Development of an HPLC analytical method for orally administered 1-substituted-2-alkyl-3-hydroxypyrid-4-one chelators in biological fluids Clin. Chem.. 36: 5–8. CASPubMedWeb of Science®Google Scholar 39 Kontoghiorghes, G. J., L. Sheppard, J. Barr, A. V. Hoffbrand, C. Bateman & N. Green. 1988. Iron balance studies in thalassaemia major patients receiving oral 1,2-dimethyl-3-hydroxypyrid-4-one Br. J. Haematol.. 69: 129. Web of Science®Google Scholar 40 Kontoghiorghes, G. J., A. N. Bartlett, A. V. Hoffbrand, J. Barr, P. Nortey, C. Bateman & N. Green. 1990. Intensive chelation and iron balance studies using oral 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in man Br. J. Haematol.. 75 (Suppl. 1): 10. PubMedWeb of Science®Google Scholar 40a Kontoghiorghes, G. J., A. N. Bartlett, A. V. Hoffbrand, J. G. Goddard, L. Sheppard, J. Barr & P. Nortey. 1990. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxyprid-4-one (L1): I. Iron chelation and metabolic studies. Br. J. Haematol. In press. 10.1111/j.1365-2141.1990.tb07887.x Google Scholar 40b Bartlett, A. N., A. V. Hoffbrand & G. J. Kontoghiorghes. 1990. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): II. Clinical observations. Br. J. Haematol. In press. 10.1111/j.1365-2141.1990.tb07888.x Web of Science®Google Scholar 40c Kontoghiorghes, G. J. 1990. Chelators affecting iron absorption in mice. Drug Res. In press. Google Scholar 41 Vreugdenhil, G., A. J. G. Swaak, G. J. Kontoghiorghes & H. G. Van Eijk. 1989. Efficacy and safety of oral iron chelator L1 in rheumatoid arthritis patients Lancet. ii: 1398. 10.1016/S0140-6736(89)92011-4 Google Scholar 42 Olivieri, N. F., G. Koren, C. Hermann, D. Chung, R. McClelland, M. Freedman, P. St. Louis & D. Templeton. 1989. Effective iron chelation with L1 in patients with thalassaemia major: Iron balance studies and dose response studies Blood. 74: 51a. Google Scholar Citing Literature Volume612, Issue1Sixth Cooley's Anemia SymposiumDecember 1990Pages 339-350 ReferencesRelatedInformation
Referência(s)